ArticleAmerican journal of physiology. Renal physiology2014
Type of MRI contrast, tissue gadolinium, and fibrosis.
Article in American journal of physiology. Renal physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Precipitation of gadolinium from magnetic resonance imaging contrast agents may be the Brass tacks of toxicity.Magnetic resonance imaging · 2025Article
- Early endolysosomal dysfunction is a contributing factor to gadolinium-based contrast agent mouse renal proximal tubule epithelial cell injury.Cell biology and toxicology · 2025Article
- Gadoteric Acid and Gadolinium: Exploring Short- and Long-Term Effects on Healthy Animals.Journal of xenobiotics · 2025Article
- Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents-A Review.International journal of molecular sciences · 2024Review
- The safety of magnetic resonance imaging contrast agents.Frontiers in toxicology · 2024Article
- The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure.Scientific reports · 2023Article
- Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.Archives of toxicology · 2022Review
- Article
- Detecting and Monitoring Hydrogels with Medical Imaging.ACS biomaterials science & engineering · 2021Review
- Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.American journal of physiology. Renal physiology · 2021Article
- Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.Histochemistry and cell biology · 2021Article
- Stability evaluation of Gd chelates for macromolecular MRI contrast agents.Magma (New York, N.Y.) · 2020Article
- Review
- Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2.The Journal of investigative dermatology · 2019Article
- Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.Toxicology and applied pharmacology · 2019Article
- Gadolinium-based contrast agents: why nephrologists need to be concerned.Current opinion in nephrology and hypertension · 2019Review
- Impact of chelation timing on gadolinium deposition in rats after contrast administration.Magnetic resonance imaging · 2019Article
- Article
- Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.Radiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
It has been presupposed that the thermodynamic stability constant (K(therm)) of gadolinium-based MRI chelates relate to the risk of precipitating nephrogenic systemic fibrosis. The present study compared low-K(therm) gadodiamide with high-K(therm) gadoteridol in cultured fibroblasts and rats with uninephrectomies. Gadolinium content was assessed using scanning electron microscopy equipped with energy-dispersive X-ray spectroscopy in paraffin-embedded tissues. In vitro, fibroblasts demonstrated dose-dependent fibronectin generation, transforming growth factor-β production, and expression of activated myofibroblast stress fiber protein α-smooth muscle actin. There were negligible differences with respect to toxicity or proliferation between the two contrast agents. In the rodent model, gadodiamide treatment led to greater skin fibrosis and dermal cellularity than gadoteridol. In the kidney, both contrast agents led to proximal tubule vacuolization and increased fibronectin accumulation. Despite large detectable gadolinium signals in the spleen, skin, muscle, and liver from the gadodiamide-treated group, contrast-induced fibrosis appeared to be limited to the skin and kidney. These findings support the hypothesis that low-K(therm) chelates have a greater propensity to elicit nephrogenic systemic fibrosis and demonstrate that certain tissues are resistant to these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.